# Larimar Therapeutics Reports First Quarter 2026 Financial and Business Update
Canonical URL: https://biopharmsignal.com/news/LRMR/larimar-therapeutics-reports-first-quarter-2026-financial-and-business-update
Ticker: LRMR
Company: Larimar Therapeutics
Source: Larimar Therapeutics
Published: 2026-05-14 11:00 EST
Original Source URL: https://investors.larimartx.com
## Summary

Intending to initiate rolling BLA seeking accelerated approval with submission of nonclinical and clinical modules in June 2026; submission of the final modules including the CMC module expected in second half of 2026  Cross-species nonclinical findings that support skin frataxin levels as a

## Article Body
Intending to initiate rolling BLA seeking accelerated approval with submission of nonclinical and clinical modules in June 2026; submission of the final modules including the CMC module expected in second half of 2026  Cross-species nonclinical findings that support skin frataxin levels as a
## Recent Company News
- 2026-05-14 11:00 EST — [Larimar Therapeutics Reports First Quarter 2026 Financial and Business Update](https://biopharmsignal.com/news/LRMR/larimar-therapeutics-reports-first-quarter-2026-financial-and-business-update) — Source: Larimar Therapeutics
- 2026-04-30 20:05 EST — [Larimar Therapeutics Publishes Cross-Species Findings Supporting Skin as a Surrogate for the Measurement of Frataxin in Tissues Clinically Relevant to Friedreich’s Ataxia](https://biopharmsignal.com/news/LRMR/larimar-therapeutics-publishes-cross-species-findings-supporting-skin-as-a-surrogate-for-the-measurement-of-frataxin-in-tissues-clinically-relevant-to-friedreich-s-ataxia) — Source: Larimar Therapeutics
- 2026-03-19 11:00 EST — [Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results](https://biopharmsignal.com/news/LRMR/larimar-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results) — Source: Larimar Therapeutics
- 2026-03-04 21:05 EST — [Larimar Therapeutics to Participate in Upcoming Investor Conferences in March](https://biopharmsignal.com/news/LRMR/larimar-therapeutics-to-participate-in-upcoming-investor-conferences-in-march) — Source: Larimar Therapeutics
- 2026-02-26 01:59 EST — [Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering](https://biopharmsignal.com/news/LRMR/larimar-therapeutics-announces-pricing-of-upsized-100-million-underwritten-public-offering) — Source: Larimar Therapeutics
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)